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Abstract 
Background: Preoperative localization of parathyroid lesions is potentially beneficial in renal patients 
with hyperparathyroidism. The aim of this study was to determine the localizing value of hybrid 
single-photon emission computed tomography combined with low-dose x-ray computed tomography 
(SPECT/LDCT) compared with SPECT alone and whether the LDCT improved reader confidence. 
Patients and methods: A retrospective study examined parathyroid scintigraphy results of patients 
previously referred with a diagnosis of renal hyperparathyroidism. All patients underwent planar 
scintigraphy using technetium-99m (99mTc)-pertechnetate, which was immediately followed with 
99mTc-sestamibi and SPECT/LDCT ~60 min after sestamibi injection and a delayed static image to 
assess differential washout. Planar subtraction images were generated. Two nuclear physicians, 
assisted by a radiologist, reported on planar+SPECT images followed by planar+SPECT/LDCT 
images. 
Results: Thirty-seven patients (males: 21; females: 16) were included (mean age 39 years, range: 
23.9–55.5). Mean creatinine level was 878 µmol/l (109–1839), mean corrected calcium level was 2.42 
mmol/l (1.77–3.64), and median parathyroid hormone level was 156.2 pmol/l (2.4 to >201). Twenty-
three patients had positive planar and SPECT results (46 lesions), six had positive planar results only, 
and eight had negative scintigraphy results. In the patients with positive planar and SPECT results, 35 
lesions were classified as eutopic and 11 as ectopic. After the addition of LDCT, localization of five 
eutopic lesions (on SPECT) was amended to ectopic locations (on SPECT/LDCT), principally by 
1
identifying posteriorly situated glands. The addition of LDCT led to increased confidence in 
localization in all cases. 
Conclusion: Compared with SPECT alone, SPECT/LDCT is beneficial in preoperative localization of 
lesions in renal hyperparathyroidism. 
 
Keywords: parathyroid scintigraphy; preoperative localization; renal hyperparathyroidism; single-
photon emission computed tomography/computed tomography 
 
Introduction 
In contrast to de-novo neoplasia or hyperplasia of one or more of the parathyroid glands in primary 
hyperparathyroidism, secondary hyperparathyroidism refers to parathyroid hyperplasia in response to a 
chronic hypocalcaemic condition (most commonly renal failure), and tertiary hyperparathyroidism 
refers to hyperplastic parathyroid glands developing functional autonomy, which is no longer 
suppressible by correction of hypocalcaemia. 
Parathyroid scintigraphy has an established role in the detection of hyperfunctioning parathyroid tissue 
when surgery is being considered 1. Scintigraphy’s main role in renal hyperparathyroidism is the 
detection of residual or recurrent hyperfunctioning glands after surgery 1–9. Routine preoperative 
scintigraphy in this patient group remains controversial. Those opposing its use cite the poor 
sensitivity and localization accuracy of the technique in multiglandular disease 5,10,11. In addition, 
renal hyperparathyroidism typically involves multiple glands and requires bilateral surgical exploration 
regardless of preoperative lesion localization. This raises questions about the value of scintigraphy to 
shorten and/or simplify surgery. Routine preoperative scintigraphy is, however, performed by some 
centres to reduce operative time and the extent of dissection.  
Reducing operative time is particularly important as these patients typically carry a high anaesthetic 
risk related to underlying medical conditions causing renal dysfunction or renal disease itself 12. In 
addition, the detection of supernumerary and ectopic glands is expected to reduce the rate of surgical 
failure 5,13–17, which, interestingly, is higher in renal hyperparathyroidism 18–21. There is no 
published literature examining the clinical impact of preoperative localization in renal 
hyperparathyroidism. 
It is expected that the higher the number of lesions detected by scintigraphy (greater sensitivity), and 
the more accurately these lesions are localized and identified as eutopic or ectopic, the more likely it is 
that preoperative scintigraphy will contribute to the management of renal hyperparathyroidism. 
There is evidence that hybrid imaging using single-photon emission computed tomography (SPECT) 
combined with low-dose x-ray computed tomography (LDCT) has no value in improving the 
sensitivity of scintigraphy compared with SPECT alone. This is true of both primary disease and renal 
hyperparathyroidism 8,22,23. There is, however, indirect evidence to suggest that LDCT improves 
localization in preoperative scintigraphy for renal hyperparathyroidism. First, more accurate 
localization was found with SPECT/LDCT in studies that mainly examined patients with primary 
hyperparathyroidism 8,23–26; second, more accurate localization has been achieved using SPECT 
fused with diagnostic-quality computed tomography (CT) in renal hyperparathyroidism 27. 
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Our institution performs SPECT/LDCT for all cases of parathyroid scintigraphy, including renal 
hyperparathyroidism. The aim of this study was to determine the impact of the LDCT component on 
lesion localization, given the additional imaging time and radiation dose involved. We hypothesized 
that the additional LDCT component would improve lesion localization and improve reader confidence 
of lesion localization. To the authors’ knowledge, no study has directly examined whether 
SPECT/LDCT has any impact in terms of lesion localization in preoperative scintigraphy of renal 
hyperparathyroidism when compared with SPECT alone. 
 
Methods 
Patient selection 
All parathyroid studies of patients with renal hyperparathyroidism referred to our department between 
February 2008 and June 2011 were reviewed retrospectively. In patients with repeat scans, a single 
study with the chronologically closest biochemical data was used. The study was conducted in 
accordance with established ethical guidelines after approval by the Health Research Ethics Committee 
of Stellenbosch University (protocol no. N11/06/197). 
 
Image acquisition 
Both subtraction and dual-phase techniques were performed using Elscint APEX SPX 4 or Elscint 
APEX SP 4 gamma cameras (General Electric Medical Systems, Milwaukee, Wisconsin, USA). 
Imaging was performed using a 3-mm pinhole collimator, with a zoom factor of 1.8 and a 256×256 
acquisition matrix. Fifteen minutes after intravenous injection of 74–111 MBq of technetium-99m 
(99mTc)-pertechnetate, two anterior images were obtained over the thyroid (with and without a marker 
over the sternal notch) at a distance of 5 cm from the collimator to the surface of the neck for 300 s 
each. Without allowing the patient to move, 740 MBq of 99mTc-sestamibi was then injected through an 
existing intravenous line, and 5 min later five consecutive planar images were obtained in the same 
way. Planar subtraction images were later generated from the acquired sestamibi and pertechnetate 
planar images. 
A single anterior image with a wider field of view was then obtained at a distance of 20 cm for 120 s. 
A delayed pinhole image was acquired after 2–3 h using the same imaging parameters as the early 
images to assess differential washout. Planar subtraction images were generated using HERMES 
MultiModality Software (Hermes Medical Solutions, Stockholm, Sweden). 
SPECT/LDCT imaging was performed 60 min after injection of sestamibi, with Infinia Hawkeye 
(General Electric Medical Systems). Projection data were acquired using a low-energy high-resolution 
collimator with a zoom factor of 1, a matrix size of 128×128 and a step and shoot protocol of 30 s/step 
and 3° per step over 360 degrees. This was immediately followed by a low-dose single-slice CT using 
a slice thickness of 10 mm, current of 2.5 mA, voltage of 140 kV, and a 256×256 matrix. The CT was 
acquired at two revolutions/min for a total imaging time of 10–12 min. The CT was reconstructed 
using a Hann filter with a cutoff frequency of 1 cycle/cm. 
Transverse SPECT images were reconstructed using an ordered subset expectation maximization 
algorithm with 16 iterations and 30 subsets, incorporating collimator blurring, scatter and attenuation 
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correction. Nonuniform attenuation correction was performed using the CT data. A Butterworth 
postprocessing filter with 1.4 cycles/cm cutoff frequency was applied to the SPECT data. 
 
Image interpretation 
Two nuclear medicine physicians and one radiologist, who were blinded to the biochemical, surgical 
and pathological results of the patients, interpreted the scintigraphic studies twice. They first reported 
the pinhole images and SPECT, and then SPECT/LDCT results. The reporters gave a consensus 
interpretation of the presence of hyperfunctioning parathyroid tissue and its location (eutopic: 
left/right, superior/inferior; ectopic: posterior, inferior, intrathyroidal, mediastinal). In addition, readers 
indicated whether or not the LDCT improved their confidence in lesion localization. Viewing of both 
planar images as well as SPECT and LDCT studies (including image fusion) was performed on a 
DELL Optiplex GX745 workstation (Dell Inc., Round Rock, Texas, USA) using programs from the 
HERMES GOLD application suite v2.11 (HERMES Display and Scale and Volume Display Software; 
Hermes Medical Solutions, Stockholm, Sweden). 
 
Measures of renal disease 
Information on the underlying renal pathology, current medical management of hyperparathyroidism, 
dialysis treatment and whether a prior renal transplant had been performed was extracted from patient 
records and recorded using a standardized data sheet. 
 
Biochemical and pathological markers 
Serum levels of parathyroid hormone (PTH) closest to the time of the scan were obtained, together 
with recently corrected calcium, phosphate and creatinine measurements. When surgery was 
performed, the pathology and location of resected tissue as well as postsurgical PTH levels were 
recorded when available. 
 
Results 
Demographics 
Of the 41 scans of patients with secondary or tertiary hyperparathyroidism eligible for inclusion, four 
scans were excluded (three scans were repeats in the same patients, whereas a fourth patient had a 
possible history of primary hyperparathyroidism). Scans from the remaining 37 patients were included 
in the study. Twenty-one male patients and 16 female patients were included with a mean age of 39 
years (range: 23.9–55.5 years). 
 
Imaging findings 
The impact of LDCT on imaging findings is summarized in Table 1. 
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Detection 
Forty-six lesions were visible on SPECT (and planar images) in 23 patients. Among these patients, 
nine had a single lesion on SPECT imaging, six had two lesions, seven had three lesions and one 
patient had four lesions. Of the 14 patients with negative SPECT, six patients had lesions visible on 
pinhole imaging and eight patients had negative results on both pinhole imaging and SPECT. These 
findings did not change with the addition of LDCT. 
 
Localization 
Of the 23 patients with lesions seen on SPECT, 15 patients had 27 lesions, all of which were thought 
to be eutopic. The remaining eight patients had 19 lesions, of which one lesion was thought to be 
ectopic in each of five patients and two were thought to be ectopic in each of three patients. Thus, of 
the 46 lesions identified on SPECT, 35 were interpreted as eutopic and 11 as ectopic. 
The addition of LDCT resulted in changes to lesion localization in five patients. All five, thought to 
have only eutopic lesions on SPECT alone, had a single lesion reclassified as ectopic. This resulted in 
30 eutopic lesions and 16 ectopic lesions. Lesions for which localization changed with the addition of 
LDCT (as well as details of the localization change) have been tabulated (Table 1). An example of 
localization change is provided in Fig. 1. The use of hybrid imaging improved the reader confidence in 
lesion localization in all cases. 
 
Incidental findings 
With the benefit of LDCT, incidental foci of sestamibi uptake were localized to vertebrae in two 
patients. 
 
Pathology and management measures 
All the patients included in our study had chronic kidney disease. The majority of patients were on 
either haemodialysis (n=25) or peritoneal dialysis (n=9). Only two patients were not on dialysis, and in 
one patient this information was not available. Twenty-nine patients were receiving calcium 
supplementation at the time of scanning, whereas five patients were not on calcium supplementation; 
this information was not available in three patients. Similarly, 24 patients were on vitamin D 
supplementation, whereas 10 patients were not on such supplementation; this information was not 
available for three patients. Fourteen patients had a history of a renal transplantation. 
Biochemistry results are summarized in Table 2. As the upper detectable limit of PTH at our institution 
is 201 pmol/l, and 11 patients exceeded this level, an accurate mean and maximum for PTH could not 
be determined (a median was therefore used). The PTH level was raised in all patients except one, in 
whom the level was inappropriately normal in the context of a raised (corrected) calcium level. An 
alternative explanation was that this normal value represented a hook effect, which was not tested for. 
The mean time intervals (range) between biochemistry results and scintigraphy were as follows: PTH – 
1.8 months (0.1–4.6 months); corrected calcium and phosphate – 1.7 months (0–4.5 months); 
creatinine – 1.7 months (0–5.1 months). 
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Of the 37 patients included in the study, 11 subsequently underwent parathyroid surgery. Records were 
available for 10 of these patients. In this subgroup, 38 lesions (histologically demonstrating 
parathyroid hyperplasia) were resected, whereas only 12 were detected on scintigraphy (identification 
rate 32%). Unfortunately, operative notes did not accurately record the location of resected glands. The 
mean mass of resected parathyroid glands was 0.91 g with values ranging from 0.1 to 3.62 g 
(normal<0.04 g). Three resected parathyroid glands (in one patient) were not weighed because of a 
laboratory oversight. 
PTH levels after surgery were available in nine patients. These demonstrated normalization in seven, 
near normalization in one and persistent elevation in one. The mean time interval between surgery and 
repeat PTH was 3.2 months (range: 0.7–8.7 months). 
 
Discussion 
In this study we found that the addition of LDCT changed the location of lesions from eutopic to 
ectopic in five out of 37 patients and improved reader confidence in lesion location in all positive 
studies. The hybrid modality also allowed the localization of other incidental pathologies in two 
patients. To our knowledge this is the first study to specifically look at the role of SPECT/LDCT in 
renal hyperparathyroidism. 
The changed localization of five lesions in five patients with the addition of LDCT in our study is 
consistent with the results of other studies that compared SPECT with SPECT/LDCT. 
Gayed et al. 22, in their study on 48 patients with primary hyperparathyroidism, compared SPECT and 
SPECT/LDCT. Reader 1 reported 40 scans as positive and reader 2 reported 38 scans as positive. The 
addition of LDCT assisted in localization in four lesions in four out of 48 patients 22. Öksüz et al. 23 
assessed preoperative SPECT/LDCT in 35 patients with mostly primary hyperparathyroidism. The 
investigators reported that SPECT/LDCT provided superior topographic information, particularly in 
patients with ectopic adenomas, although the number of lesions in which LDCT changed localization 
was not reported 23. 
It is possible that SPECT/LDCT may make a greater contribution in patients with a multinodular 
goitre. Serra et al. 8 compared SPECT and SPECT/LDCT in 16 patients with hyperparathyroidism, of 
whom 12 had a multinodular goitre. In their study, LDCT changed localization in a large proportion of 
patients – seven out of 14 lesions in six out of 10 patients in the primary group and seven out of nine 
lesions in five out of six patients in the secondary group 8. In 33 patients with concomitant primary 
hyperparathyroidism and multinodular goitre, Pata et al. 25 reported that, when SPECT was compared 
with SPECT/LDCT in different groups, SPECT/LDCT was found to be more accurate in lateralizing 
parathyroid lesions. Change in localization of individual lesions was not studied 25. 
Of the five lesions in which LDCT resulted in changed localization in our study, three were 
reclassified as being posteriorly situated. This is consistent with previous findings demonstrating that 
LDCT improves the detection of posteriorly situated glands. In the study by Serra et al. 8, in three 
patients (all with primary disease) additional LDCT identified a posteriorly situated (retrotracheal) 
gland. Lavely et al. 24, in their study on patients with primary hyperparathyroidism, reported that the 
major benefit of the hybrid modality (incorporating LDCT) was its ability to distinguish inferior from 
inferoposterior glands (situated in the tracheo-oesophageal groove). 
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Not all studies have reported a benefit with LDCT. In a retrospective comparison between the accuracy 
of localization of SPECT (n=165) and that of SPECT/LDCT (n=131) in primary hyperparathyroidism, 
the authors found no difference in the accuracy of lesion localization between the two groups. This 
result may, however, be related to the two modalities being compared in different patients 28. 
Similarly, Gayed et al. 22 reported that SPECT/CT did not detect more ectopic lesions compared with 
SPECT alone in a study of patients with primary disease. 
In this study, nuclear medicine physicians were assisted by a radiologist with good knowledge of 
variations in parathyroid anatomy. It is worth noting that without sound anatomical knowledge the 
impact of LDCT may not be fully realized. 
Reader confidence in localization improved in all our cases with the addition of LDCT. This is 
consistent with a report by Jacene et al. 29 on the advantages of hybrid imaging with SPECT/LDCT 
over SPECT alone in which the authors stated, ‘functional images often lack the anatomic detail 
necessary for accurate lesion localisation, which can decrease reader confidence in image 
interpretation and lead to uncertain or erroneous interpretations’. 
Very little research has been directed towards the clinical impact of LDCT in preoperative imaging of 
hyperparathyroidism. In a study by Serra et al. 8, hybrid imaging resulted in a modification of the 
surgical approach in three out of 10 patients with primary disease when lesions were determined to be 
posteriorly situated. Lavely et al. 24, commenting on the ability of SPECT/LDCT to distinguish 
between inferior and inferior–posterior localizations, pointed out that surgery for a gland in the 
inferior–posterior location is frequently more complex because of its intimate association with the 
recurrent laryngeal nerve and that preoperative knowledge of this ectopic location facilitates surgical 
exploration.  
In a study by Pata et al. 25 in patients with concomitant primary hyperparathyroidism and multinodular 
goitre, the mean operative time was less in the SPECT/LDCT group compared with the SPECT group. 
In addition, at least two studies in primary hyperparathyroidism mention reductions in operation time, 
or facilitation of resection with the use of SPECT/LDCT, although neither of these studies directly 
compared SPECT and SPECT/LDCT in terms of a surgical or clinical outcome measure 30,31. 
The lesions localized to vertebrae in two patients on LDCT represent potentially important incidental 
findings. The differential diagnosis of these lesions includes brown tumours and metastatic lesions. No 
subsequent record of malignancy was found in the medical records of these patients and these lesions 
were hypothesized to represent brown tumours. 
Literature on the impact of LDCT on parathyroid scintigraphy in terms of incidental findings is 
limited. Treglia et al. 32 describe a case of primary hyperparathyroidism in which SPECT/LDCT 
localized a lesion with sestamibi uptake to the third left rib, which was subsequently demonstrated to 
be a brown tumour. Brown tumours may occur in renal hyperparathyroidism and are known to take up 
sestamibi 33–38. Vertebral brown tumours are reportedly rare 39. 
A limitation of this retrospective study was that no information was available on the clinical impact of 
the scintigraphy, or on the findings during surgery. It is assumed that SPECT/LDCT is more accurate 
when its findings are discordant with those of SPECT. Previously, however, hybrid imaging has been 
found to be 100% accurate in lesion localization when correlated with surgical findings 8. 
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By virtue of its improved references to anatomical landmarks, it is probable that any differences in 
localization between SPECT and SPECT/LDCT in our group would reflect a deficiency of SPECT in 
terms of localization. 
Similarly, although LDCT changed lesion localization in five out of 37 patients, there are no measures 
of the impact of the information on patient management (e.g. changed surgical approach, changed 
anaesthetic plan). 
An additional limitation is that SPECT was commenced 1 h after MIBI injection, which is relatively 
late. This is likely to account for six patients with lesions detected on planar imaging but not on 
SPECT 24. It is possible that the impact of SPECT/LDCT may have been greater if SPECT had been 
performed earlier. Similarly, the identification rate of 32% would probably have been higher with 
earlier SPECT. 
Finally, this study was limited to a single consensus report by a group of three doctors. As such, it 
provides no measures of the inter-reporter or intra-reporter variability of findings. 
 
Conclusion 
In patients with renal hyperparathyroidism, the addition of LDCT results in better localization of 
hyperfunctioning parathyroid tissue and improved reader confidence. These improvements are likely to 
have a significant impact on further patient management. 
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Figures 
 
Figure 1 
 
Fig. 1. Example of the ability of LDCT to distinguish between eutopic gland (a) and posteriorly-situated gland 
(b) indicated by solid arrows. Transverse images from left to right: SPECT, fused (windowing and background 
adjusted) SPECT/LDCT, and LDCT. LDCT, low-dose x-ray computed tomography; SPECT, single-photon 
emission computed tomography. 
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